Have a personal or library account? Click to login
Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration Cover

Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration

Acta Marisiensis - Seria Medica
Volume 68 (2022): Issue 1 (March 2022)
By: M Vivek Reddy,  GNK Ganesh,  B Babu,  Ramesh Jagadeesan and  Praharsh Kumar MR  
Open Access
|Apr 2022

Download Article

Download the full article as a PDF file.

DOI: https://doi.org/10.2478/amma-2022-0004 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Journal RSS Feed
Language: English
Page range: 28 - 34
Submitted on: Dec 6, 2021
Accepted on: Mar 7, 2022
Published on: Apr 13, 2022
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
generic drug exclusivity,
competitive generic therapy,
patent challenge exclusivity
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2022 M Vivek Reddy, GNK Ganesh, B Babu, Ramesh Jagadeesan, Praharsh Kumar MR, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 68 (2022): Issue 1 (March 2022)Next article